Partners Capital Investment Group Holdings LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 7.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 155,349 shares of the company’s stock after purchasing an additional 10,378 shares during the quarter. Johnson & Johnson accounts for 3.9% of Partners Capital Investment Group Holdings LLC’s investment portfolio, making the stock its 11th biggest holding. Partners Capital Investment Group Holdings LLC’s holdings in Johnson & Johnson were worth $19,349,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently made changes to their positions in the business. State Street Corp lifted its holdings in shares of Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after buying an additional 6,656,371 shares during the period. Korea Investment CORP lifted its holdings in shares of Johnson & Johnson by 38.9% in the 1st quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock valued at $265,296,000 after buying an additional 596,134 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $65,598,000. CIBC World Markets Inc. lifted its holdings in shares of Johnson & Johnson by 111.8% in the 1st quarter. CIBC World Markets Inc. now owns 948,655 shares of the company’s stock valued at $118,155,000 after buying an additional 500,662 shares during the period. Finally, State of Tennessee Treasury Department lifted its holdings in shares of Johnson & Johnson by 23.0% in the 1st quarter. State of Tennessee Treasury Department now owns 2,072,592 shares of the company’s stock valued at $258,142,000 after buying an additional 387,937 shares during the period. Institutional investors own 66.00% of the company’s stock.
In related news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.
Several research firms have recently commented on JNJ. J P Morgan Chase & Co raised their price target on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a report on Tuesday, August 15th. Wells Fargo & Company reaffirmed a “market perform” rating and set a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Cowen and Company set a $147.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a report on Thursday, August 24th. Finally, BidaskClub cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 1st. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $134.60.
Shares of Johnson & Johnson (JNJ) traded up 0.20% during midday trading on Friday, hitting $134.45. The stock had a trading volume of 15,522,011 shares. The company’s 50-day moving average price is $132.62 and its 200-day moving average price is $129.18. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The firm has a market cap of $360.86 billion, a price-to-earnings ratio of 22.75 and a beta of 0.79.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.74 earnings per share. Equities research analysts forecast that Johnson & Johnson will post $7.18 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were issued a $0.84 dividend. The ex-dividend date was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.50%. Johnson & Johnson’s payout ratio is currently 56.76%.
ILLEGAL ACTIVITY WARNING: This story was first posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.truebluetribune.com/2017/09/17/johnson-johnson-jnj-shares-bought-by-partners-capital-investment-group-holdings-llc.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.